Maegim한국어

메디톡스

086900KOSDAQSector: Pharma & Biotech
₩69,000▲ 0.73%Market cap ₩503.6BAs of Jul 21, 2026 close · updated once daily
B
Grade B58.3 ptsTop 38% of 2,523 stocks
Financial strength
64.6
Growth momentum
44.0
Price attractiveness
61.4

As of Jul 21, 2026 close · This grade is not a buy/sell recommendation — it is information mechanically scored from public data using a fixed formula.

1

Financial strength

64.6
How much debt does it carry relative to equity?
Debt-to-equity ratio
28.1%
✓ Above median · Top 27% in sector
Sector median 51.5%
Can it cover what's due within a year?
Current ratio
148.2%
✗ Below median · Top 57.9% in sector
Sector median 191.3%
How much of revenue becomes profit?
Operating margin
6.9%
✓ Above median · Top 24.9% in sector
Sector median -2.3%
How much did it earn on its own capital?
ROE (return on equity)
3.7%
✓ Above median · Top 31.9% in sector
Sector median -4.5%

Source filing: annual report (consolidated) — view original ↗

2

Growth momentum

44.0
How much did revenue grow in a year?
Revenue growth (YoY)
8.2%
✓ Above median · Top 43.6% in sector
Sector median 6.4%
Has it grown steadily over three years?
Revenue 3-year CAGR
8.2%
✓ Above median · Top 37.6% in sector
Sector median 4.9%
Did core profits grow in a year?
Operating income change (YoY)
-16.4%
✗ Below median · Top 68.5% in sector
Sector median 3.6%
Are core profits higher than three years ago?
Operating income change (3Y)
-63.6%
✗ Below median · Top 74.5% in sector
Sector median 3.5%

Source filing: annual report (consolidated) — view original ↗

3

Price attractiveness

61.4
Is the price expensive relative to earnings?
P/E (price-to-earnings)
30.3x
✓ Above median · Top 32.3% in sector
Sector median P/E of profitable peers 14.4x · 57% loss-making
Is the price expensive relative to book value?
P/B (price-to-book)
1.11x
✓ Above median · Top 44.9% in sector
Sector median 1.39x

Valuation uses the Jul 21, 2026 close and market cap

Grade distribution of 248 stocks in Pharma & Biotech

S1A52B66C51D61F15